Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity [0.03%]
RAS基因突变在急性髓系白血病中的临床意义：涉及的基因和突变复杂性决定其预后价值
John N Colgan,Jack H Peplinski,Yi-Cheng Wang et al.
John N Colgan et al.
Acute myeloid leukemia (AML) is a heterogeneous disease with complex mutational profiles that lead to variable clinical outcomes. NRAS and KRAS are among the most frequently mutated genes in AML, but their clinical impact has not been well-...
Paul Imbach
Paul Imbach
Abdelrahman Noureldin,Marc Carrier
Abdelrahman Noureldin
Revisiting KIR Restriction and CD94 Expression in Diagnostic Criteria for NK-Large Granular Lymphocytic Leukemia [0.03%]
关于限制性KIR表达和CD94在NK型大颗粒淋巴细胞白血病诊断标准中的价值的再评价研究
Jansen N Seheult,Gregory E Otteson,Dragan Jevremovic et al.
Jansen N Seheult et al.
A long first intron of PROS1 modulates protein S expression across tissues in mice and humans [0.03%]
PROS1的第一个长内含子通过调节鼠和人组织中的蛋白S表达水平在血管炎发病机制中起作用
Keiko Maruyama,Sheng Ye,Yuka Eura et al.
Keiko Maruyama et al.
Introns can modulate gene expression through enhancer- or silencer-like elements, as well as intron-mediated enhancement. Protein S (PS), encoded by PROS1, is an anticoagulant cofactor for activated protein C and tissue factor pathway inhib...
Aaron J Wilk,Jean S Oak,Erik Ames
Aaron J Wilk
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance) [0.03%]
一项儿科方案治疗Ph阴性年轻成人ALL的长期随访结果——CALGB 10403（联盟）研究十年生存分析
Wellington F Silva Jr,Jun Yin,Michaela Liedtke et al.
Wellington F Silva Jr et al.
Disease Extent, Not Lesion Location, Determines Relapse Risk in Single-System Skeletal Langerhans Cell Histiocytosis [0.03%]
单系统骨骼郎格汉斯细胞组织细胞增生症复发风险由病变范围而非位置决定
Itziar Astigarraga,Helga Björk Arnardóttir,Oussama Abla et al.
Itziar Astigarraga et al.
Langerhans cell histiocytosis (LCH) confined to the skeleton has excellent survival, yet optimal management of multifocal bone disease and lesions at traditionally defined "special sites" remains uncertain due to limited prospective data. W...
Gilteritinib + chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial [0.03%]
针对复发/难治FLT3-ITD阳性AML儿童患者开展的吉列替尼联合化疗临床研究(SKIPPER)结果报告
Philip Connor,Raul C Ribeiro,Albert Catala et al.
Philip Connor et al.
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) occurs in ~15% of pediatric patients with acute myeloid leukemia (AML) and is associated with high relapse risk with conventional chemotherapy. Gilteritinib is a selective, n...
Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML [0.03%]
单细胞长读取转录本基因分型揭示了后MPN AML克隆演进的离散机制
Julian Grabek,Jasmin M Straube,Leanne Cooper et al.
Julian Grabek et al.
Myeloproliferative neoplasms (MPNs) are caused by acquired mutations in hematopoietic stem and progenitor cells (HSPCs). The acquisition of additional mutations like TP53 and the overall mutational burden influence a patient's risk of disea...